VolitionRx Limited (NYSE:VNRX - Get Free Report) insider Jacob Vincent Micallef purchased 43,691 shares of VolitionRx stock in a transaction dated Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $24,903.87. Following the completion of the acquisition, the insider now owns 394,352 shares of the company's stock, valued at approximately $224,780.64. The trade was a 12.46 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
VolitionRx Stock Performance
VolitionRx stock opened at $0.57 on Wednesday. The stock has a market capitalization of $53.28 million, a price-to-earnings ratio of -1.60 and a beta of 1.17. VolitionRx Limited has a 52-week low of $0.43 and a 52-week high of $1.23. The stock's 50 day moving average price is $0.69 and its two-hundred day moving average price is $0.67.
Hedge Funds Weigh In On VolitionRx
An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its position in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,959 shares of the company's stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
Discover the coin set to explode before 2025!
Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW
VNRX has been the topic of several analyst reports. StockNews.com initiated coverage on VolitionRx in a report on Friday, December 6th. They issued a "sell" rating on the stock. D. Boral Capital reiterated a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a report on Tuesday. Finally, Benchmark reiterated a "hold" rating on shares of VolitionRx in a report on Friday, November 22nd.
Check Out Our Latest Report on VNRX
VolitionRx Company Profile
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
